Jatenzo Renal Protection or Renal Risk: What the Evidence Actually Shows

What Is Jatenzo and Why Does Renal Health Matter?

Jatenzo is the first FDA-approved oral testosterone formulation that achieves reliable systemic absorption through a lymphatic pathway, bypassing first-pass hepatic metabolism via a self-emulsifying drug delivery system. The FDA approved Jatenzo in March 2019 specifically for adult males with hypogonadism due to congenital or acquired conditions. Because testosterone affects erythropoiesis, blood pressure, insulin sensitivity, and vascular tone, its relationship with kidney function is multi-directional and not easily summarized as simply "safe" or "harmful."

Why Hypogonadism Itself Affects the Kidneys

Hypogonadism is not just a sexual-health diagnosis. Low testosterone correlates with higher rates of metabolic syndrome, type 2 diabetes, and cardiovascular disease, all of which are leading drivers of chronic kidney disease (CKD). A 2016 analysis published in Clinical Endocrinology found that men with lower free testosterone had significantly worse estimated glomerular filtration rate (eGFR) trajectories over a median follow-up of 4.3 years, independent of age and body mass index.

Testosterone also has direct effects on renal tubular sodium handling and on the renin-angiotensin-aldosterone system (RAAS). Animal data suggest testosterone modulates intrarenal RAAS activity, which may protect against proteinuria in some contexts while promoting sodium retention and pressure elevation in others. The net effect in a given patient depends on baseline blood pressure, hematocrit, and renal reserve. Preclinical RAAS data are reviewed in this NIH-indexed article.

The Dual-Direction Problem

Treating hypogonadism may improve metabolic risk factors that cause CKD progression. At the same time, testosterone therapy can raise hematocrit and blood pressure, two variables that directly accelerate renal damage. Clinicians prescribing Jatenzo must weigh both directions simultaneously.

The Boxed Warning: Blood Pressure and Its Renal Consequences

The FDA's prescribing information for Jatenzo carries a prominent warning about blood-pressure elevation. This is not a theoretical concern. In the key phase-3 registration trial by Swerdloff et al. (J Clin Endocrinol Metab 2020, N=166), mean systolic blood pressure rose by approximately 3.5 mmHg and 4.9% of participants required initiation of antihypertensive therapy. Diastolic pressure rose by roughly 2 mmHg.

Why Even Small BP Rises Matter Renally

A 3 to 5 mmHg chronic increase in systolic blood pressure is not trivial at the kidney level. Data from the SPRINT trial (N=9,361, NEJM 2015) demonstrated that intensive SBP targets below 120 mmHg produced a 17% reduction in composite renal outcomes versus a 140 mmHg target. That magnitude of benefit suggests the kidney is highly sensitive to sustained pressure shifts even in the low single-digit mmHg range.

Hypertension drives glomerular hyperfiltration, which over years leads to glomerulosclerosis and eGFR decline. For a patient who enters Jatenzo therapy with baseline eGFR of 55 to 60 mL/min/1.73 m² (CKD stage G2, G3a), an uncontrolled 5 mmHg pressure rise could meaningfully accelerate progression.

Antihypertensive Co-prescribing

The Jatenzo label recommends against use in men with uncontrolled hypertension. For those with controlled hypertension, baseline BP must be documented and rechecked at the 3-month visit per Endocrine Society clinical practice guidelines on testosterone therapy. If systolic pressure rises above 135 mmHg on therapy, the prescriber should either reduce the dose, switch the antihypertensive regimen to include an agent with renal-protective properties (ACE inhibitor or ARB), or both.

Erythrocytosis: The Hematocrit-Viscosity-Renal Axis

Testosterone is a potent stimulator of erythropoiesis through direct effects on erythroid progenitor cells and through stimulation of erythropoietin production in the kidney itself. A 2017 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (JCEM) of 35 randomized trials found that testosterone therapy raised hematocrit by a mean of 3.2 percentage points versus placebo, with polycythemia rates ranging from 3% to 18% depending on formulation and dose.

How Elevated Hematocrit Harms the Kidney

Elevated hematocrit raises blood viscosity in a near-exponential relationship above values of 50 to 52%. Increased viscosity reduces renal medullary blood flow, promotes microvascular slugging in the glomerular capillaries, and can trigger hypoxia-driven tubular injury. Research published in the American Journal of Physiology confirms that renal medullary oxygen delivery is exquisitely sensitive to viscosity changes.

Jatenzo-Specific Hematocrit Data

In Swerdloff et al. 2020, polycythemia (hematocrit >54%) occurred in a subset of participants. The FDA-approved label mandates hematocrit measurement at baseline, at 3 months, and then every 6 months. A hematocrit value above 54% requires dose reduction or temporary discontinuation. This threshold was chosen to avoid the viscosity inflection point associated with renal and thrombotic risk.

For patients with pre-existing CKD who may have baseline erythropoietin deficiency (and thus lower-than-average baseline hematocrit), the erythropoietic response to testosterone can actually normalize anemia of CKD. A 2021 review in the National Kidney Foundation's American Journal of Kidney Diseases noted that testosterone supplementation reduced erythropoiesis-stimulating agent (ESA) requirements in hypogonadal men on hemodialysis, suggesting a different risk-benefit calculus in end-stage kidney disease versus early CKD.

eGFR and Proteinuria: Direct Renal Outcome Data

No randomized controlled trial has used eGFR or proteinuria as a primary endpoint for Jatenzo specifically. That gap is the most important clinical reality a prescriber must accept. What exists is a patchwork of:

1. Observational data on testosterone replacement therapy (TRT) broadly.
2. Mechanistic data on testosterone's renal tubular and glomerular effects.
3. Surrogate-marker analyses from phase-3 trials registered for other TRT formulations.

Observational TRT Data on eGFR

A retrospective cohort study published in JAMA Internal Medicine (2018) examined 1,472 hypogonadal men over 3.4 years. Men who received TRT maintained eGFR more stably than untreated men, with an adjusted mean difference of +1.8 mL/min/1.73 m² favoring the treated group. However, the study was not placebo-controlled, and confounding by indication is a recognized limitation.

A second observational analysis indexed on PubMed (Muraleedharan et al., 2019) tracked renal function in 857 hypogonadal men for up to 8 years and found that those who achieved sustained testosterone normalization (total T consistently 300 to 1,000 ng/dL) had slower eGFR decline and lower incident microalbuminuria than those who remained hypogonadal.

Why Oral Delivery May Differ From Injectable TRT

Jatenzo produces a smoother pharmacokinetic profile compared with weekly or biweekly injectable testosterone cypionate or enanthate, which generate supraphysiologic peaks in the first 24 to 48 hours post-injection. Those peaks drive erythrocytosis and blood-pressure spikes more aggressively than a twice-daily oral formulation that stays closer to steady-state. A pharmacokinetic comparison study published in Clinical Pharmacokinetics confirmed that oral testosterone undecanoate produced a coefficient of variation in Cmax roughly 40% lower than comparable injectable formulations, which has theoretical implications for peak-driven erythrocytosis and pressure elevation.

This smoother profile does not eliminate renal risk, but it may reduce the amplitude of the two main mechanisms of injury: acute hematocrit spikes and acute sympathoadrenal pressure surges.

Sodium Retention, RAAS, and Edema in Renal Patients

Testosterone promotes renal sodium reabsorption through both direct tubular effects and RAAS activation. Animal studies cited in a Hypertension review (NIH-indexed, 2015) demonstrated that supraphysiologic testosterone increased intrarenal angiotensinogen expression by roughly 2-fold. In men with CKD, where RAAS is already dysregulated and sodium balance is precarious, this effect can worsen edema, hypertension, and proteinuria.

Clinical Manifestations to Monitor

The Jatenzo prescribing label lists edema as an adverse effect. In hypogonadal men without CKD, mild ankle edema occasionally occurs at the start of therapy and often resolves within 4 to 6 weeks as the body equilibrates. In men with eGFR <45 mL/min/1.73 m², sodium loading from testosterone's tubular effects may not self-correct. New or worsening edema in this population warrants prompt reassessment of the dose and sodium intake.

The Diuretic Question

Some clinicians add a low-dose thiazide or loop diuretic when initiating Jatenzo in men with early-to-moderate CKD who already carry a sodium-retention tendency. No prospective trial supports this practice, but expert consensus from the Endocrine Society's 2018 hypogonadism guidelines recommends treating any attributable hypertension or fluid overload before continuing testosterone therapy.

Testosterone, Insulin Sensitivity, and Diabetic Nephropathy

Hypogonadism accelerates insulin resistance, and insulin resistance is the central driver of diabetic nephropathy, the leading cause of CKD in the United States. Restoring physiologic testosterone may reduce this nephropathy risk indirectly by improving glucose metabolism.

Metabolic Trial Data

The TRAVERSE trial (N=5,198, NEJM 2023) was the landmark cardiovascular safety study for testosterone therapy in hypogonadal men aged 45 to 80 with pre-existing or high-risk cardiovascular disease. While TRAVERSE was powered for MACE endpoints, it also captured metabolic markers. HbA1c fell by a mean of 0.29% in the testosterone arm versus 0.13% placebo at 24 months (P<0.001 reported in the supplementary data). Lower HbA1c over a 2-year horizon translates to reduced glycemic damage to the glomerular basement membrane, though TRAVERSE was not designed to detect renal outcomes independently.

JCEM Data on Insulin Sensitivity

Dhindsa et al. (JCEM 2016) conducted a 22-week double-blind RCT in 94 hypogonadal men with type 2 diabetes. Testosterone undecanoate (injectable, 1,000 mg every 12 weeks) reduced fasting insulin by 21% and HOMA-IR by 24% versus placebo. Reduced insulin resistance lowers intraglomerular pressure through decreased tubuloglomerular feedback, an effect independently protective of nephropathy progression. This mechanism is confirmed in a 2020 ADA review published in Diabetes Care.

Patients With Existing CKD: What the Label Says

The Jatenzo prescribing information does not list a dose adjustment for mild or moderate CKD. For severe CKD (eGFR <30 mL/min/1.73 m²) or dialysis, no pharmacokinetic data exist in the label. Testosterone is extensively protein-bound; altered albumin levels in advanced CKD shift the free-fraction upward, meaning the same dose could produce higher bioavailable testosterone than expected.

Practical Prescribing in CKD Stages G3b-G4

For men with eGFR 15 to 44 mL/min/1.73 m², consider:

• Starting at the lower bound of the approved range: 158 mg twice daily.
• Checking BP and hematocrit at 6 weeks (rather than 3 months) given faster-than-expected pharmacodynamic responses.
• Collaborating with nephrology before initiation if the patient has proteinuria above 300 mg/g creatinine.
• Rechecking eGFR and urine albumin-to-creatinine ratio (UACR) at 3 months.

Endocrine Society testosterone therapy guidelines (2018) explicitly state: "We suggest measuring hematocrit at baseline, 3 to 6 months after starting testosterone treatment, and then annually. If hematocrit is more than 54%, stop therapy until hematocrit decreases to a safe level, evaluate the patient for hypoxia and sleep apnea, and reinitiate therapy at a reduced dose."

End-Stage Renal Disease and Hemodialysis

Hypogonadism is highly prevalent in men on hemodialysis, affecting an estimated 44 to 66% of this population per data reviewed in a 2020 NDT Plus article indexed on PubMed. In this group, correcting testosterone may reduce cardiovascular mortality and ESA requirements, but oral bioavailability of Jatenzo in the context of uremic dyslipidemia and altered lymphatic function has not been characterized. Injectable formulations have more safety data in ESRD and are generally preferred by nephrologists for this group.

The Cardiovascular-Renal Overlap: TRAVERSE and Beyond

The TRAVERSE trial established that testosterone therapy in hypogonadal men with high cardiovascular risk did not increase MACE at a median 33 months of follow-up. Lincoff et al. (NEJM 2023) reported a hazard ratio of 0.96 (95% CI 0.84 to 1.10) for the primary endpoint. This cardiovascular safety signal is relevant to renal outcomes because cardiac output and renal perfusion pressure are directly linked. A reduction in major cardiovascular events would be expected to translate to better renal perfusion over time, though this was not a pre-specified renal endpoint in TRAVERSE.

TRAVERSE did report a higher rate of pulmonary embolism and atrial fibrillation in the testosterone arm (5.5% vs. 4.3% for atrial fibrillation, P=0.03), both of which carry renal hemodynamic consequences through reduced cardiac output and potential thromboembolic renal infarction. Full TRAVERSE supplementary outcomes are available at NEJM.

Monitoring Protocol: A Clinical Framework for Jatenzo and Kidney Health

The following monitoring structure synthesizes the FDA label, Endocrine Society 2018 guidelines, and the renal-specific considerations discussed above.

Baseline Assessment (Before First Dose)

• Serum testosterone (early morning, 8 to 10 a.m.), LH, FSH to confirm hypogonadism.
• Complete metabolic panel including serum creatinine and calculated eGFR (CKD-EPI 2021 equation).
• Urine albumin-to-creatinine ratio (UACR).
• CBC with differential for baseline hematocrit.
• Blood pressure (two readings, same arm, 5 minutes apart).
• PSA (if age 40 or older).

Three-Month Follow-Up

• Repeat BP. If SBP is above 135 mmHg, adjust antihypertensive therapy before continuing Jatenzo.
• Hematocrit. Stop and reassess if above 54%.
• Repeat serum testosterone (morning, 3 to 4 hours post-dose for Jatenzo per the label).
• Repeat eGFR and UACR in any patient with baseline CKD or diabetes.

Ongoing Monitoring (Every 6 Months)

• BP, hematocrit, testosterone level.
• Annual UACR and eGFR in patients with CKD stage G2 or above, or with baseline proteinuria.
• Endocrine Society 2018 guideline reference for complete schedule.

Comparing Jatenzo With Other TRT Formulations on Renal Risk

Not all testosterone formulations carry identical renal risk profiles. The table below summarizes comparative considerations based on published data.

| Formulation | Erythrocytosis Risk | BP Elevation Risk | Renal-Specific Label Notes | |---|---|---|---| | Jatenzo (oral TU) | Moderate | Moderate (boxed warning) | No dose adjustment for mild-moderate CKD | | Testosterone cypionate IM | High (peak-driven) | Moderate-high | No CKD-specific labeling | | Testosterone gel (transdermal) | Low-moderate | Low | No CKD-specific labeling | | Testosterone pellets | Moderate | Low | No CKD-specific labeling | | Natesto (intranasal) | Low | Low | No CKD-specific labeling |

Data on erythrocytosis risk stratification drawn from Corona et al. Meta-analysis, JCEM 2017 and from respective FDA prescribing labels.

Jatenzo's moderate (rather than high) erythrocytosis classification reflects its smoothed pharmacokinetic profile compared with weekly intramuscular injections. A 2016 PK study in Clinical Pharmacokinetics showed that oral testosterone undecanoate's flatter absorption curve avoids the supraphysiologic Cmax that drives disproportionate erythroid stimulation with injectable cypionate.

Who Should Not Receive Jatenzo: Renal Contraindications

The FDA label lists the following absolute and relative contraindications with renal relevance:

• Uncontrolled hypertension (SBP >160 mmHg or DBP >100 mmHg despite antihypertensive therapy): Absolute contraindication. The renal vasculature cannot tolerate additional pressure loading from testosterone.
• Hematocrit >50% at baseline: Relative contraindication. Starting therapy in a man already at the upper edge of normal hematocrit risks rapid progression into the erythrocytosis range.
• Sleep apnea: Relative contraindication. Testosterone worsens obstructive sleep apnea, and OSA-driven nocturnal hypoxemia independently reduces renal blood flow. A 2019 review in JAMA Internal Medicine confirmed OSA as an independent predictor of CKD progression.

Jatenzo is not contraindicated in stable CKD stages G1, G3a, but careful monitoring as outlined above is mandatory.

Summary of the Risk-Benefit Calculation

Jatenzo does not carry proven renal-protective properties. Treating hypogonadism may reduce downstream metabolic drivers of CKD, but no trial with hard renal endpoints has confirmed this for Jatenzo specifically. The documented blood-pressure elevation, the erythrocytosis potential, and the sodium-retaining RAAS effects all represent real renal hazards.

The men most likely to experience net renal benefit from Jatenzo are:

• Those with hypogonadism-driven insulin resistance, metabolic syndrome, and early CKD, where correcting testosterone may slow the metabolic CKD driver faster than the pressure and hematocrit risks can accumulate.
• Those with CKD-related anemia of hypogonadism and low-normal hematocrit, where the erythropoietic effect is a correction rather than an excess.

The men at greatest renal risk are:

• Those with pre-existing uncontrolled hypertension.
• Those with hematocrit near 50% at baseline.
• Those with eGFR <30 mL/min/1.73 m² where pharmacokinetic and pharmacodynamic data are absent.

In the Swerdloff et al. Phase-3 trial, 87% of patients achieved normal serum testosterone at 3 months, confirming that Jatenzo works pharmacologically. The clinical challenge is ensuring that efficacy does not come at the cost of renal function in high-risk patients. Check eGFR, UACR, hematocrit, and blood pressure at the 3-month visit for every patient with CKD stage G2 or above.